Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Shelly Heimfeld
Fred Hutchinson Cancer Research Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Nohla Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Heimfeld is the Scientific Director of the cGMP Cell Processing Facility that is part of the Shared Resources Core - Therapeutic Manufacturing Cell Processing supported by this grant. This Core supports the development and manufacture of innovative cell-based therapies for Phase I/II clinical testing. The cGMP facility permits the reproducible production of large-scale quantities of therapeutic cells under strict quality control and safety conditions. The facility may be producing products under contract with Nohla or for use in research funded by Nohla or designed to test a Nohla product. This in turn could impact the value of Dr. Heimfeld’s financial interest in Nohla in terms of increased equity value and continued payments for consulting services.
Cancer Center Support Grant
There were an estimated 1.6 million new cases of cancer in the United States in 2013, and an estimated 580,000 deaths from the disease. Cancer is the second leading cause of the death in the U.S. The goal of the Fred Hutchinson/University of Washington Cancer Consortium is the elimination of cancer through more effective prevention, diagnosis, and treatment, deriving from fundamental insights into the biology of the disease.
Filed on May 24, 2016.
Tell us what you know about Shelly Heimfeld's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Shelly Heimfeld”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Shelly Heimfeld | Fred Hutchinson Cancer Research Center | Conflict of Interest | Nohla Therapeutics | $80,000 - $99,999 |
| Shelly Heimfeld | Fred Hutchinson Cancer Research Center | Conflict of Interest | Nohla Therapeutics | Value cannot be readily determined |
| Shelly Heimfeld | Fred Hutchinson Cancer Research Center | Conflict of Interest | Nohla Therapeutics | $80,000 - $99,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.